North America Genome Editing Market to have a positive growth rate during 2016-2
Posted by rohan on November 7th, 2017
The North America Genome Editing Market was worth USD 1.13 billion in 2016 and estimated to be growing at a CAGR of 13.98%, to reach USD 2.18 billion by 2021. Genome editing or gene editing is the insertion, deletion or replacement of DNA at a specific site in the genome of an organism or a cell. It is usually carried out in a laboratory using engineered nucleases which are alternatively called as molecular scissors. There are a number of recognized gene editing methods which have been used effectively in applying in a wide range of tissues and organisms including human cancer cells and IPSCs.
Genome Editing can be categorized based on whether they result in the loss of function or gain of function. In the former, functional forms of a genome are removed and the effect is studied and in the latter new active forms of the genome are introduced and the effect is studied. Some common examples of genome editing are target validation, drug repurposing, studying modulators of gene transcription and identifying lethal synthetic interactions.
The key drivers of the Genome Editing Market in North America include the development of gene therapy in the US and increasing use of GM crops. Other factors driving the market include the high incidence of Alzheimer’s disease, dementia, cancer and infectious diseases. The market is also driven by the growing availability of research grants and funding and the numerous workshops and conferences held on genome editing standards. Inspite of the numerous drivers, the market is hampered by concerns such as ethicality of genome editing as brought up by human and animal rights activists. Additionally, the market is restrained by the concern of toxicity due to nucleases affecting non-target DNA sequences.
The North America Genome Editing market is broadly classified into Cell Line, Animal Genetic and Plant Genetic Engineering in the basis of application, by technology into CRISPR, TALEN, ZFN, Antisense and Other Technologies and on the basis of end user into Biotechnological & Pharmaceutical Companies, Academic and Government Research Institutes and Contract Research Organizations. Based on geography, the North America market is analysed under USA and Canada. North America is the largest market globally albeit with the second lowest growth rate. The less than average growth rate is deemed acceptable due to the highly developed nature of the market. This is also made up by the fact that 40% of the total market revenue generated from genome editing comes from the North American region.
Free sample of the report is available @ http://www.marketdataforecast.com/market-reports/north-america-genome-editing-market-2792/request-sample
The Genome Editing market is highly competitive with a large number of players. Some of the major ones are Thermo Fisher Scientific, Merck KGAA, Horizon Discovery Group Plc, Genscript Biotech Corporation, Sangamo Biosciences, Integrated DNA Technologies, Lonza Group Ltd, New England Biolabs, Origene Technologies, and Transposagen Biopharmaceuticals.
3) End User
Reasons to buy North America Genome Editing Market Research Report:
Like it? Share it!
About the Authorrohan
Joined: September 20th, 2017
Articles Posted: 1,346
More by this author